$NHI
National Health Investors Inc Stock $nhi

$nhi Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000087786017000051 Filed on May 09, 2017

Income Statement

Concept	2017 Q1	2016 Q1	2015 Q4
Revenue	$66.39M	$59.02M	$58.64M
YoY Change	12.49%	5.86%	28.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.430M	$3.340M	$3.270M
YoY Change	32.63%	-20.1%	59.51%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$16.14M	$13.73M	$13.70M
YoY Change	17.56%	5.64%	41.24%
% of Gross Profit
Operating Expenses	$32.24M	$27.33M	$16.93M
YoY Change	17.94%	6.77%	43.96%
Operating Profit	$34.14M	$31.69M
YoY Change	7.75%
Interest Expense	$11.66M	$10.26M	$12.37M
YoY Change	13.63%	21.99%	-310.37%
% of Operating Profit	34.15%	32.39%
Other Income/Expense, Net		$160.0K	$710.0K
YoY Change		77.78%
Pretax Income	$44.23M	$31.69M	$54.79M
YoY Change	39.59%	5.09%	94.98%
Income Tax
% Of Pretax Income
Net Earnings	$44.23M	$32.73M	$54.40M
YoY Change	35.16%	10.25%	97.58%
Net Earnings / Revenue	66.62%	55.45%	92.76%
Basic Earnings Per Share	$1.11	$0.85	$1.44
Diluted Earnings Per Share	$1.10	$0.85	$1.44
COMMON SHARES
Basic Shares Outstanding	39.95M shares	38.40M shares	37.73M shares
Diluted Shares Outstanding	40.11M shares	38.41M shares	37.74M shares

Balance Sheet

Concept	2017 Q1	2016 Q1	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.700M	$4.197M	$24.84M
YoY Change	35.81%	-0.07%	33.56%
Cash & Equivalents	$5.685M	$4.197M	$13.09M
Short-Term Investments		$0.00	$11.75M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$2.700M	$4.000M	$3.260M
Other Receivables	$77.00M	$65.00M	$59.70M
Total Short-Term Assets	$85.40M	$97.80M	$76.30M
YoY Change	-12.68%	102.07%	80.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.268B	$1.841B	$1.837B
YoY Change	23.2%	4.15%	3.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$7.254M	$7.657M
YoY Change		-88.61%	-18.75%
Other Assets	$4.100M	$3.800M	$6.000M
YoY Change	7.89%	-85.27%	-76.92%
Total Long-Term Assets	$2.431B	$2.061B	$2.057B
YoY Change	17.91%	4.57%	5.99%
TOTAL ASSETS
Total Short-Term Assets	$85.40M	$97.80M	$76.30M
Total Long-Term Assets	$2.431B	$2.061B	$2.057B
Total Assets	$2.516B	$2.159B	$2.133B
YoY Change	16.52%	6.91%	7.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.60M	$24.80M	$19.40M
YoY Change	-12.9%	67.57%	23.57%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$83.00M	$80.60M	$73.30M
YoY Change	2.98%	18.53%	10.73%
LONG-TERM LIABILITIES
Long-Term Debt	$1.146B	$937.1M	$914.4M
YoY Change	22.26%	4.19%	5.99%
Other Long-Term Liabilities		$1.800M	$3.000M
YoY Change		-68.97%	-26.83%
Total Long-Term Liabilities	$1.146B	$938.9M	$917.4M
YoY Change	22.03%	3.72%	5.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$83.00M	$80.60M	$73.30M
Total Long-Term Liabilities	$1.146B	$938.9M	$917.4M
Total Liabilities	$1.229B	$1.020B	$990.8M
YoY Change	20.51%	3.7%	6.19%
SHAREHOLDERS EQUITY
Retained Earnings			$19.86M
YoY Change
Common Stock	$1.255B	$1.086B	$1.086B
YoY Change	15.55%		4.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.287B	$1.131B	$1.133B
YoY Change
Total Liabilities & Shareholders Equity	$2.516B	$2.159B	$2.133B
YoY Change	16.52%	6.91%	7.58%

Cashflow Statement

Concept	2017 Q1	2016 Q1	2015 Q4
OPERATING ACTIVITIES
Net Income	$44.23M	$32.73M	$54.40M
YoY Change	35.16%	10.25%	97.58%
Depreciation, Depletion And Amortization	$16.14M	$13.73M	$13.70M
YoY Change	17.56%	5.64%	41.24%
Cash From Operating Activities	$48.68M	$41.30M	$43.60M
YoY Change	17.87%	7.09%	32.52%
INVESTING ACTIVITIES
Capital Expenditures	-$118.0M	-$9.500M	-$2.200M
YoY Change	1142.11%	196.88%	-99.55%
Acquisitions
YoY Change
Other Investing Activities	-$2.400M	-$4.800M	$24.70M
YoY Change	-50.0%	-87.94%	-374.44%
Cash From Investing Activities	-$120.4M	-$14.30M	$22.40M
YoY Change	742.5%	-66.8%	-104.54%
FINANCING ACTIVITIES
Cash Dividend Paid	$35.86M	$32.64M
YoY Change	9.88%	13.07%
Common Stock Issuance & Retirement, Net	$79.80M	$0.00
YoY Change
Debt Paid & Issued, Net	$196.0K	$189.0K
YoY Change	3.7%	3.28%
Cash From Financing Activities	$72.62M	-$11.48M	-67.00M
YoY Change	-732.65%	-312.57%	-114.55%
NET CHANGE
Cash From Operating Activities	$48.68M	$41.30M	43.60M
Cash From Investing Activities	-$120.4M	-$14.30M	22.40M
Cash From Financing Activities	$72.62M	-$11.48M	-67.00M
Net Change In Cash	$853.0K	$15.52M	-1.000M
YoY Change	-94.5%	1618.94%	233.33%
FREE CASH FLOW
Cash From Operating Activities	$48.68M	$41.30M	$43.60M
Capital Expenditures	-$118.0M	-$9.500M	-$2.200M
Free Cash Flow	$166.7M	$50.80M	$45.80M
YoY Change	228.12%	21.63%	-91.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000877860
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40981915	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	NATIONAL HEALTH INVESTORS INC
CY2015Q4	nhi	Accounts Receivableand Other Assets AccountsReceivableandOtherAssets	9017000	USD
CY2016Q1	nhi	Accounts Receivableand Other Assets AccountsReceivableandOtherAssets	2703000	USD
CY2016Q1	nhi	Amortization Of Financing Costs Exclusive Of Amounts Written Off AmortizationOfFinancingCostsExclusiveOfAmountsWrittenOff	868000	USD
CY2017Q1	nhi	Amortization Of Financing Costs Exclusive Of Amounts Written Off AmortizationOfFinancingCostsExclusiveOfAmountsWrittenOff	906000	USD
CY2017Q1	nhi	Convertible Debt Instrument Conversion Ratio Principal Amount Basis ConvertibleDebtInstrumentConversionRatioPrincipalAmountBasis	1000	USD
CY2017Q1	nhi	Credit Facility Current Revolving Borrowing Capacity CreditFacilityCurrentRevolvingBorrowingCapacity	550000000	USD
CY2017Q1	nhi	Debt Instrument Variable Interest Rate Reference Rate Basis Points DebtInstrumentVariableInterestRateReferenceRateBasisPoints	98
CY2016Q1	nhi	Franchise Excise And Other Taxes FranchiseExciseAndOtherTaxes	283000	USD
CY2017Q1	nhi	Franchise Excise And Other Taxes FranchiseExciseAndOtherTaxes	267000	USD
CY2016Q1	nhi	Lessee Payment To Acquire Purchase Option LesseePaymentToAcquirePurchaseOption	0	USD
CY2017Q1	nhi	Lessee Payment To Acquire Purchase Option LesseePaymentToAcquirePurchaseOption	1250000	USD
CY2017Q1	nhi	Notes Receivable Funding Commitment NotesReceivableFundingCommitment	42239000	USD
CY2017Q1	nhi	Maximum Commitment For All Active Development Projects MaximumCommitmentForAllActiveDevelopmentProjects	129800000	USD
CY2017Q1	nhi	Nonemployeedirectorannualstockgrants Nonemployeedirectorannualstockgrants	20000	shares
CY2017Q1	nhi	Nonportfolio Assets Original Cost NonportfolioAssetsOriginalCost	1267000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5731000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3079000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1173588000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1254780000	USD
CY2017Q1	nhi	Number Of Health Care Properties Related To Mortgage Notes Receivables NumberOfHealthCarePropertiesRelatedToMortgageNotesReceivables	9	properties
CY2017Q1	nhi	Number Of Lessees NumberOfLessees	29
CY2017Q1	nhi	Real Estate Investment Property Portfolio Assets RealEstateInvestmentPropertyPortfolioAssets	2596057000	USD
CY2017Q1	nhi	Real Estate Investments During The Period RealEstateInvestmentsDuringThePeriod	119261000	USD
CY2017Q1	nhi	Remaining Unfunded Development Commitment RemainingUnfundedDevelopmentCommitment	55208000	USD
CY2017Q1	nhi	Variable Interest Entity Number Of Entities Not Primary Beneficiary VariableInterestEntityNumberOfEntitiesNotPrimaryBeneficiary	8
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	20874000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	21599000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	313080000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	329173000	USD
CY2017Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	116000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	979000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1523000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2016Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	68000	USD
CY2017Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	104000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	885000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1337000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	75050	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19851	shares
CY2016Q4	us-gaap	Assets Assets	2403633000	USD
CY2017Q1	us-gaap	Assets Assets	2515979000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1680000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13286000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28808000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4832000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5685000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15522000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	853000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.90
CY2017Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.95
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39847860	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40978934	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39847860	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40978934	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	398000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	410000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	31083000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	35420000	USD
CY2017Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1160729000	USD
CY2014Q1	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	7762000	USD
CY2017Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	70.75
CY2017Q1	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	14.13
CY2016Q4	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	29873000	USD
CY2017Q1	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	35173000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	384000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	31467000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	35420000	USD
CY2017Q1	us-gaap	Construction And Development Costs ConstructionAndDevelopmentCosts	74592000	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	15729000	USD
CY2017Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	18018000	USD
CY2014Q1	us-gaap	Convertible Debt ConvertibleDebt	192238000	USD
CY2016Q4	us-gaap	Convertible Debt ConvertibleDebt	195283000	USD
CY2017Q1	us-gaap	Convertible Debt ConvertibleDebt	195577000	USD
CY2017Q1	us-gaap	Debt Instrument Convertible If Converted Value In Excess Of Principal DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal	5302000	USD
CY2017Q1	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	2826680	shares
CY2017Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.039
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5889000	USD
CY2016Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1115981000	USD
CY2017Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1145691000	USD
CY2016Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	72518000	USD
CY2017Q1	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	77024000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	13733000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	16154000	USD
CY2016Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	13733000	USD
CY2017Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	16154000	USD
CY2017Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	38930000	USD
CY2016Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	35863000	USD
CY2017Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	38930000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.85
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.11
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.10
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1644000	USD
CY2015Q4	us-gaap	Escrow Deposit EscrowDeposit	8208000	USD
CY2016Q1	us-gaap	Escrow Deposit EscrowDeposit	8208000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	1665000	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	10088000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	1654000	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	50000	USD
CY2016Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	1654000	USD
CY2017Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	50000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2929000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4108000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.85
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.11
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.85
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.10
CY2016Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-402000	USD
CY2017Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2016Q1	us-gaap	Income Loss From Subsidiaries Tax Expense Benefit IncomeLossFromSubsidiariesTaxExpenseBenefit	-161000	USD
CY2017Q1	us-gaap	Income Loss From Subsidiaries Tax Expense Benefit IncomeLossFromSubsidiariesTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-752000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2306000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-110000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	657000	USD
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	98048	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	13144	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	56910	shares
CY2016Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	121000	USD
CY2017Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	67000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	10262000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	11661000	USD
CY2016Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9515000	USD
CY2017Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	10822000	USD
CY2016Q1	us-gaap	Interest Income Operating InterestIncomeOperating	3160000	USD
CY2017Q1	us-gaap	Interest Income Operating InterestIncomeOperating	3089000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	7678000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	9164000	USD
CY2016Q4	us-gaap	Investment Building And Building Improvements InvestmentBuildingAndBuildingImprovements	2285122000	USD
CY2017Q1	us-gaap	Investment Building And Building Improvements InvestmentBuildingAndBuildingImprovements	2396383000	USD
CY2016Q1	us-gaap	Investment Income Net InvestmentIncomeNet	784000	USD
CY2017Q1	us-gaap	Investment Income Net InvestmentIncomeNet	162000	USD
CY2016Q4	us-gaap	Land Land	172003000	USD
CY2017Q1	us-gaap	Land Land	182923000	USD
CY2016Q1	us-gaap	Legal Fees LegalFees	126000	USD
CY2017Q1	us-gaap	Legal Fees LegalFees	56000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	1194043000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	1228695000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2403633000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2515979000	USD
CY2016Q4	us-gaap	Line Of Credit LineOfCredit	158000000	USD
CY2017Q1	us-gaap	Line Of Credit LineOfCredit	187000000	USD
CY2016Q1	us-gaap	Line Of Credit Facility Increase Decrease For Period Net LineOfCreditFacilityIncreaseDecreaseForPeriodNet	-22000000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Increase Decrease For Period Net LineOfCreditFacilityIncreaseDecreaseForPeriodNet	-29000000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	800000000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Unused Capacity Commitment Fee Percentage LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage	40
CY2017Q1	us-gaap	Loans And Leases Receivable Commitments Fixed Rates LoansAndLeasesReceivableCommitmentsFixedRates	117000000	USD
CY2016Q4	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	133493000	USD
CY2017Q1	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	150098000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	801000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive	519443000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive	200916000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	437885000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	856000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	828000	USD
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	11745000	USD
CY2016Q1	us-gaap	Marketable Securities MarketableSecurities	0	USD
CY2016Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	11000	USD
CY2017Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	10038000	USD
CY2016Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	11000	USD
CY2017Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	10038000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11479000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72622000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14296000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-120444000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	41297000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	48675000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	32725000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	44230000	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	384000	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	450000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	824000	USD
CY2017Q1	us-gaap	Number Of Real Estate Properties NumberOfRealEstateProperties	206	properties
CY2017Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	32
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	27333000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	32246000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	31685000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	34142000	USD
CY2016Q1	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	55074000	USD
CY2017Q1	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	63137000	USD
CY2015Q4	us-gaap	Other Assets OtherAssets	33016000	USD
CY2016Q1	us-gaap	Other Assets OtherAssets	15021000	USD
CY2016Q4	us-gaap	Other Assets OtherAssets	33016000	USD
CY2017Q1	us-gaap	Other Assets OtherAssets	15021000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1642000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8810000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2016Q1	us-gaap	Payments To Acquire Mortgage Notes Receivable PaymentsToAcquireMortgageNotesReceivable	20774000	USD
CY2017Q1	us-gaap	Payments To Acquire Mortgage Notes Receivable PaymentsToAcquireMortgageNotesReceivable	28338000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	10038000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-1013000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-789000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-5480000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	465000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2825000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-26000	USD
CY2016Q1	us-gaap	Other Noncash Income OtherNoncashIncome	150000	USD
CY2017Q1	us-gaap	Other Noncash Income OtherNoncashIncome	271000	USD
CY2016Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1665000	USD
CY2017Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	10088000	USD
CY2016Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	453000	USD
CY2017Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	994000	USD
CY2016Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	32637000	USD
CY2017Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	35863000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	218000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	116000	USD
CY2016Q1	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	9463000	USD
CY2017Q1	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	118011000	USD
CY2016Q1	us-gaap	Payments To Develop Real Estate Assets PaymentsToDevelopRealEstateAssets	7640000	USD
CY2017Q1	us-gaap	Payments To Develop Real Estate Assets PaymentsToDevelopRealEstateAssets	3842000	USD
CY2016Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	435000	USD
CY2017Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	USD
CY2017Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	200000000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79797000	USD
CY2016Q1	us-gaap	Proceeds From Real Estate And Real Estate Joint Ventures ProceedsFromRealEstateAndRealEstateJointVentures	3000000	USD
CY2017Q1	us-gaap	Proceeds From Real Estate And Real Estate Joint Ventures ProceedsFromRealEstateAndRealEstateJointVentures	450000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Collection Of Mortgage Notes Receivable ProceedsFromSaleAndCollectionOfMortgageNotesReceivable	3985000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Collection Of Mortgage Notes Receivable ProceedsFromSaleAndCollectionOfMortgageNotesReceivable	12109000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17049000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	18182000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	33109000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	44230000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2472854000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2597324000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2159774000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2268151000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	189000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	196000	USD
CY2015Q4	us-gaap	Replacement Reserve Escrow ReplacementReserveEscrow	4046000	USD
CY2016Q1	us-gaap	Replacement Reserve Escrow ReplacementReserveEscrow	4110000	USD
CY2016Q1	us-gaap	Revenues Revenues	59018000	USD
CY2017Q1	us-gaap	Revenues Revenues	66388000	USD
CY2016Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	21325000	USD
CY2017Q1	us-gaap	Security Deposit Liability SecurityDepositLiability	22475000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	541679	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	979178	shares
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y11M4D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y4M0D
CY2017Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	79797000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1523000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.062
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.053
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.191
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.197
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0091
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0149
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	731662	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	585827	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.65
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.75
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	741676	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1085010	shares
CY2016Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	979000	USD
CY2017Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1523000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1209590000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1287284000	USD
CY2016Q1	us-gaap	Straight Line Rent StraightLineRent	5286000	USD
CY2017Q1	us-gaap	Straight Line Rent StraightLineRent	5755000	USD
CY2016Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	9740000	USD
CY2017Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	9149000	USD
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	38401647	shares
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	39953804	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38414791	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40108762	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38401647	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39953804	shares
CY2017Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> - We have reclassified certain balances where necessary to conform the presentation of prior periods to the current period. We have combined our investment in marketable securities into other assets in our Condensed Consolidated Balance Sheets.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates -</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000877860-17-000051-index-headers.html	Edgar Link	pending
0000877860-17-000051-index.html	Edgar Link	pending
0000877860-17-000051.txt	Edgar Link	pending
0000877860-17-000051-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nhi-20170331.xml	Edgar Link	completed
nhi-20170331.xsd	Edgar Link	pending
nhi-20170331_cal.xml	Edgar Link	unprocessable
nhi-20170331_def.xml	Edgar Link	unprocessable
nhi-20170331_lab.xml	Edgar Link	unprocessable
nhi-20170331_pre.xml	Edgar Link	unprocessable
nhi-3312017x10q.htm	Edgar Link	pending
nhi-3312017x10qex311.htm	Edgar Link	pending
nhi-3312017x10qex312.htm	Edgar Link	pending
nhi-3312017x10qex32.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NHI
National Health Investors Inc Stock $nhi

2017 Q1 Form 10-Q Financial Statement

#000087786017000051 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NHI National Health Investors Inc Stock $nhi

2017 Q1 Form 10-Q Financial Statement

#000087786017000051 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NHI
National Health Investors Inc Stock $nhi